Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1. (Withdrawn) A method for treating ischemic heart diseases, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1.

2. (Withdrawn) The method for treating ischemic heart diseases according to claim 1, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1, and in which a vascular endothelial growth factor is not administered.

3. (Withdrawn) The method according to claim 1 or 2, wherein the vector encoding angiopoietin-1 is a viral vector.

4. (Withdrawn) The method according to claim 3, wherein the viral vector is an adenoviral vector.

5. (Withdrawn) The method according to claim 3, wherein the viral vector is a minus-strand RNA viral vector.

6. (Withdrawn) The method according to claim 1 or 2, wherein the vector encoding angiopoietin-1 is a naked DNA.

7. (Withdrawn) The method according to any one of claims 1 to 6, wherein the vector encoding angiopoietin-1 is a vector that drives angiopoietin-1 expression using a CA promoter or a promoter having a transcriptional activity equivalent to or higher than that of said CA promoter.

8. (Withdrawn) The method according to any one of claims 1 to 7, wherein the administration of angiopoietin-1 or the vector encoding angiopoietin-1 is an injection into cardiac muscle.

9. (Withdrawn) A method for treating ischemic diseases, which comprises the step of administering a viral vector encoding angiopoietin-1.

10. (Withdrawn) The method for treating ischemic diseases according to claim 9, which comprises the step of administering a viral vector encoding angiopoietin-1, and wherein a vascular endothelial growth factor is not administered.

11. (Withdrawn) The method according to claim 9 or 10, wherein the viral vector

is an adenoviral vector.

12. (Withdrawn) The method according to claim 9 or 10, wherein the viral vector is a minus-strand RNA viral vector.

13. (Withdrawn) The method according to any one of claims 9 to 12, wherein the vector administration is an injection into an ischemic site.

14. (Cancelled)

15. (Withdrawn) The mesenchymal cell according to claim 14, into which an adenoviral vector encoding angiopoietin-1 has been introduced.

16. (Currently Amended) ~~The~~ An isolated mesenchymal cell ~~according to claim 14, into which~~ comprising a minus-strand RNA viral vector encoding angiopoietin-1 ~~has been introduced~~.

17. (Currently Amended) A therapeutic composition for ischemia, which comprises the mesenchymal cell according to ~~any one of claims 14 to~~ claim 16 and a pharmaceutically acceptable carrier.

18. (Withdrawn) A method for producing a genetically modified mesenchymal cell, wherein the method comprises the step of contacting the mesenchymal cell with a minus-strand RNA viral vector carrying a gene.

19. (Withdrawn) The method according to claim 18, wherein the gene encodes angiopoietin-1.

20. (Previously Presented) The mesenchymal cell according to claim 16, wherein the minus-strand RNA viral vector is a Sendai viral vector.

21. (Previously Presented) A therapeutic composition for ischemia, which comprises the mesenchymal cell according to claim 20.

22. (New) The mesenchymal cell according to claim 16, wherein the cell is a mesenchymal stem cell.

23. (New) The mesenchymal cell according to claim 20, wherein the cell is a mesenchymal stem cell.

24. (New) The therapeutic composition according to claim 17, wherein the cell is

a mesenchymal stem cell.

25. (New) The therapeutic composition according to claim 21, wherein the cell is a mesenchymal stem cell.